{
    "nct_id": "NCT06121232",
    "official_title": "Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study",
    "inclusion_criteria": "* Ability to understand and the willingness to sign a written informed consent document\n* Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds\n* Patients seen at Pain Management Center at MD Anderson Cancer Center\n* Patient ages greater or equal to 18 years but less than or equal to 85 years\n\nExclusion Criteria\n\n* Patients with cognitive dysfunction\n* Patient with recent history (<6 months) of drug or alcohol abuse\n* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}